XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

Cash

 

$

63,396

 

 

$

135,819

 

Commercial paper

 

 

36,016

 

 

 

 

Money market funds

 

 

12,288

 

 

 

19,881

 

U.S. government bonds

 

 

1,988

 

 

 

 

Total cash and cash equivalents

 

$

113,688

 

 

$

155,700

 

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments

The Company’s investments consist primarily of available-for-sale debt investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands):

 

 

 

December 31, 2023

 

 

 

Amortized Cost

 

 

Gross Unrealized
Holding Gains

 

 

Gross Unrealized
Holding Losses

 

 

Estimated
Fair Value

 

Corporate bonds

 

$

13,988

 

 

$

9

 

 

$

(5

)

 

$

13,992

 

Commercial paper

 

 

52,273

 

 

 

 

 

 

 

 

 

52,273

 

U.S. government bonds

 

 

45,783

 

 

 

20

 

 

 

 

 

 

45,803

 

Agency bonds

 

 

9,830

 

 

 

1

 

 

 

(1

)

 

 

9,830

 

Total investments

 

$

121,874

 

 

$

30

 

 

$

(6

)

 

$

121,898

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2022

 

 

 

Amortized Cost

 

 

Gross Unrealized
Holding Gains

 

 

Gross Unrealized
Holding Losses

 

 

Estimated
Fair Value

 

Corporate bonds

 

$

83,080

 

 

$

 

 

$

(1,072

)

 

$

82,008

 

Commercial paper

 

 

57,381

 

 

 

 

 

 

 

 

 

57,381

 

U.S. government bonds

 

 

112,547

 

 

 

5

 

 

 

(1,207

)

 

 

111,345

 

Agency bonds

 

 

11,690

 

 

 

 

 

 

(222

)

 

 

11,468

 

Asset-backed securities

 

 

2,484

 

 

 

 

 

 

(10

)

 

 

2,474

 

Foreign government bonds

 

 

5,007

 

 

 

 

 

 

(27

)

 

 

4,980

 

Convertible promissory note

 

 

1,000

 

 

 

 

 

 

 

 

 

1,000

 

Total investments

 

$

273,189

 

 

$

5

 

 

$

(2,538

)

 

$

270,656

 

Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position

The following table summarizes, for all available for sale securities in an unrealized loss position, the fair value and gross unrealized loss by length of time the security has been in a continual unrealized loss position (in thousands):

 

 

 

December 31, 2023

 

 

 

Less than 12 Months

 

 

12 Months or More

 

 

Total

 

 

 

Estimated
Fair Value

 

 

Gross Unrealized
Holding Losses

 

 

Estimated
Fair Value

 

 

Gross Unrealized
Holding Losses

 

 

Estimated
Fair Value

 

 

Gross Unrealized
Holding Losses

 

Corporate bonds

 

$

 

 

$

 

 

$

3,495

 

 

$

(5

)

 

$

3,495

 

 

$

(5

)

U.S. government bonds

 

 

4,984

 

 

 

 

 

 

 

 

 

 

 

 

4,984

 

 

 

 

Agency bonds

 

 

4,987

 

 

 

(1

)

 

 

 

 

 

 

 

 

4,987

 

 

 

(1

)

Total

 

$

9,971

 

 

$

(1

)

 

$

3,495

 

 

$

(5

)

 

$

13,466

 

 

$

(6

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2022

 

 

 

Less than 12 Months

 

 

12 Months or More

 

 

Total

 

 

 

Estimated
Fair Value

 

 

Gross Unrealized
Holding Losses

 

 

Estimated
Fair Value

 

 

Gross Unrealized
Holding Losses

 

 

Estimated
Fair Value

 

 

Gross Unrealized
Holding Losses

 

Corporate bonds

 

$

6,738

 

 

$

(147

)

 

$

75,270

 

 

$

(925

)

 

$

82,008

 

 

$

(1,072

)

U.S. government bonds

 

 

22,326

 

 

 

(13

)

 

 

67,909

 

 

 

(1,194

)

 

 

90,235

 

 

 

(1,207

)

Agency bonds

 

 

 

 

 

 

 

 

11,468

 

 

 

(222

)

 

 

11,468

 

 

 

(222

)

Asset-backed securities

 

 

2,474

 

 

 

(10

)

 

 

 

 

 

 

 

 

2,474

 

 

 

(10

)

Foreign government bonds

 

 

 

 

 

 

 

 

4,980

 

 

 

(27

)

 

 

4,980

 

 

 

(27

)

Total

 

$

31,538

 

 

$

(170

)

 

$

159,627

 

 

$

(2,368

)

 

$

191,165

 

 

$

(2,538

)

 

Schedule of Inventory

Inventories consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

Raw materials

 

$

1,376

 

 

$

1,241

 

Work-in-progress

 

 

34,614

 

 

 

36,003

 

Finished goods

 

 

5,575

 

 

 

3,192

 

Total inventories

 

$

41,565

 

 

$

40,436

 

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

Contract assets

 

$

26,481

 

 

$

17,488

 

Deferred revenues from associated contracts

 

 

(26,481

)

 

 

(17,488

)

Net contract assets

 

 

 

 

 

 

Insurance proceeds receivable for litigation settlement

 

 

28,500

 

 

 

 

Prepaid assets

 

 

6,644

 

 

 

9,730

 

Other current assets

 

 

6,711

 

 

 

4,353

 

Total prepaid expenses and other current assets

 

$

41,855

 

 

$

14,083

 

Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

Leasehold improvements

 

$

102,109

 

 

$

102,580

 

Laboratory equipment

 

 

22,757

 

 

 

21,175

 

Machinery

 

 

9,454

 

 

 

9,642

 

Computer equipment

 

 

9,490

 

 

 

9,486

 

Furniture and fixtures

 

 

6,184

 

 

 

6,200

 

Construction in progress

 

 

62

 

 

 

204

 

Total property and equipment

 

$

150,056

 

 

$

149,287

 

Less: accumulated depreciation

 

 

(136,930

)

 

 

(128,682

)

Property and equipment, net

 

$

13,126

 

 

$

20,605

 

Schedule of Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

Preclinical and clinical trial accruals

 

$

27,663

 

 

$

57,780

 

API and bulk drug product price true-up

 

 

50,978

 

 

 

75,055

 

Litigation settlement

 

 

28,500

 

 

 

 

Payroll and related accruals

 

 

20,267

 

 

 

22,562

 

Accrued co-promotion expenses - current

 

 

10,309

 

 

 

36,677

 

Roxadustat profit share to AstraZeneca

 

 

7,084

 

 

 

7,280

 

Property taxes and other taxes

 

 

6,615

 

 

 

7,691

 

Professional services

 

 

7,103

 

 

 

5,480

 

Current portion of liability related to sale of future revenues

 

 

5,654

 

 

 

 

Accrued restructuring charge

 

 

3,697

 

 

 

 

Other

 

 

5,021

 

 

 

7,248

 

Total accrued and other current liabilities

 

$

172,891

 

 

$

219,773